Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab With Gemcitabine and Cisplatin Versus Standard of Care Chemoimmunotherapy in Advanced Biliary Tract Cancer
NCT07765433Phase 3Not yet recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Jan 2027
- Primary completion
- Dec 2028
01
Overview
A Phase 3 trial of ivonescimab in biliary tract cancer (BTC), sponsored by ECOG-ACRIN Cancer Research Group. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07765433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07765433.